Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymalfasin Plus PEG-Interferon in Hep C Non-Responders
NCT00040027Phase 3Completed
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Apr 2002
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C virus infection comparing Thymalfasin + PEG-IFN with Placebo + PEG-IFN (2 arms). Primary endpoint: Sustained Virologic Response at 72 weeks. Started Apr 2002; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00040027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040027.